Cyclosporine A Protects Retinal Explants against Hypoxia

Area of Science:

• Ophthalmology
• Neuroscience
• Pharmacology

Background:

• Retinal hypoxia is a major cause of vision loss in various eye diseases.
• Cyclosporine A (CsA), an immunosuppressant, shows neuroprotective properties in neurological conditions.
• The retinal tolerance and efficacy of CsA against hypoxia are unknown.

Purpose of the Study:

• To determine the biocompatibility and neuroprotective potential of Cyclosporine A (CsA) in rat retinal explants.
• To identify the optimal CsA concentration for protecting retinal ganglion cells (RGCs) from hypoxic injury.

Main Methods:

• Rat retinal explants were exposed to varying CsA concentrations (1-9 µg/mL).
• Immunohistochemistry (Brn3a, TUNEL), optical coherence tomography (OCT), and multielectrode array (MEA) recordings were used.
• Retinas underwent hypoxic insult followed by CsA treatment to assess neuroprotection.

Main Results:

• CsA at concentrations up to 9 µg/mL was well-tolerated by RGCs and microglia.
• A CsA concentration of 9 µg/mL demonstrated significant neuroprotection against hypoxia.
• CsA treatment counteracted hypoxia-induced RGC loss, reduced apoptosis, and preserved retinal thickness.

Conclusions:

• Cyclosporine A (CsA) effectively protects retinal ganglion cells (RGCs) from hypoxia-induced damage.
• The tested CsA concentrations are well-tolerated in retinal tissue.
• Further in vivo research is warranted to explore local CsA therapy for hypoxic retinal diseases.